Drugs / Aluminum Phosphate
Aluminum Phosphate
also known as
Aluminum · ACH · aluminium phosphate · aluminum acetate · Aluminum Adjuvant · Aluminum Chloride · Aluminum Chloride Hexahydrate · Maalox
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DOMEBORO | — | 1976-04-30 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07401277 | Feb 2026 → Jul 2027 expected | actinic keratosis | West Virginia University | Recruiting | No outcome recorded |
| Phase 1 | NCT02304185 | Dec 2014 → Apr 2016 | — | Crucell Holland BV | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06748404 | Mar 2025 → Dec 2027 expected | — | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 2 | NCT01960686 | Oct 2013 → Apr 2014 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03416348 Comparator | May 2018 → Jan 2022 | isolated hyperchlorhidrosis | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00347555 Background | May 2006 → Apr 2008 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02935686 Background | Mar 2017 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02273570 Background | Mar 2015 → Dec 2016 | secondary hyperparathyroidism of renal origin | Azienda Ospedaliera Sant'Anna | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aluminum phosphate | “The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.” NCT02304185 ↗2“Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.” NCT02935686 ↗ |
| Known as | ACH | “5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)” NCT07401277 ↗ |
| Known as | aluminium phosphate | “Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48.” NCT02935686 ↗ |
| Known as | Aluminum | “A rescue therapy with aluminum("Maalox®") is allowed for no more than 30 days.” NCT02273570 ↗ |
| Known as | aluminum acetate | “TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.” NCT06748404 ↗ |
| Known as | Aluminum Adjuvant | “Dose 1 of Aluminum Adjuvant” NCT01960686 ↗ |
| Known as | Aluminum Chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03416348 ↗ |
| Known as | Aluminum Chloride Hexahydrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07401277 ↗ |
| Known as | Maalox | “A rescue therapy with aluminum("Maalox®") is allowed for no more than 30 days.” NCT02273570 ↗ |
| Modality | Other / unclassified | “aluminum adjuvant” NCT01960686 ↗ |
| Route | Intramuscular | “Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.” NCT02935686 ↗ |